DNMT inhibitors such as azacytidine can demethylate endothelial nitric oxide synthases (eNOS) which is reduced in SSc patients, and thus, is a possible therapeutic target (Matouk and Marsden, 2008). The gene discussed is DNMT1; the disease is systemic sclerosis.